相似文献
1
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
N Engl J Med. 2020 Nov 26;383(22):2188. doi: 10.1056/NEJMc2029828.
2
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
N Engl J Med. 2020 Nov 26;383(22):2189. doi: 10.1056/NEJMc2029828.
3
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
N Engl J Med. 2020 Nov 26;383(22):2188-2189. doi: 10.1056/NEJMc2029828.
4
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. Reply.
N Engl J Med. 2020 Nov 26;383(22):2189-2190. doi: 10.1056/NEJMc2029828.
5
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
N Engl J Med. 2020 Aug 20;383(8):743-753. doi: 10.1056/NEJMoa1916525.
6
Evolution of atypical femur fractures and the association with bisphosphonates.
Bull Hosp Jt Dis (2013). 2014;72(1):104-9.
7
[Bisphosphonate-associated atypical fractures of the femur: an update of the current evidence].
Lakartidningen. 2019 Sep 16;116:FMUU.
8
Bilateral atypical femur fractures without bisphosphonate exposure.
Skeletal Radiol. 2017 Feb;46(2):241-247. doi: 10.1007/s00256-016-2526-0. Epub 2016 Nov 30.
9
Antiresorptive Therapies for Osteoporosis.
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):555-60. doi: 10.1016/j.coms.2015.07.001. Epub 2015 Sep 26.
10
Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
Orthopedics. 2010 Dec;33(12):902. doi: 10.3928/01477447-20101021-21.
Zotero 插件